Jonathan Shannon - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Jonathan Shannon

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Journal of Medicinal Chemistry|May 19, 2018

Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Hannah Braithwaite, et al.

Journal of Medicinal Chemistry|August 13, 2021

Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Luke Bevan, et al.

Cancer Discovery|January 12, 2021

Targeting the p300/CBP Axis in Lethal Prostate CancerJonathan Welti, Adam Sharp, Nigel Brooks, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Journal of Medicinal Chemistry|May 19, 2018

Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Hannah Braithwaite, et al.

Journal of Medicinal Chemistry|August 13, 2021

Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Luke Bevan, et al.

Cancer Discovery|January 12, 2021

Targeting the p300/CBP Axis in Lethal Prostate CancerJonathan Welti, Adam Sharp, Nigel Brooks, et al.

Pageof 2